🔗 Share this article

An underground market for unlicensed weight-loss drugs is propelled by social media fitness personalities and vendors on communication apps, based on new investigations.

Experimental Treatment Gaining Popularity Via Social Media

Retatrutide, which is still in research studies, is being advertised by online personalities for its alleged weight-reducing effects. Followers are urged to message these profiles directly for source information, while also receiving promotional offers.

Active Commerce on Social Networks

Separately, a robust market exists on messaging services, where groups with numerous of participants share comparison images, administration instructions and claims of rapid UK delivery. Sellers market the substance there before redirecting buyers to other platforms for transactions.

Understanding Retatrutide

Retatrutide is an investigational injectable created by American pharmaceutical company Eli Lilly. The treatment targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials indicate it could help individuals lose up to 25% of their body weight. Nicknamed the “triple G”, the substance is being promoted digitally as the successor to Ozempic.

Healthcare Experts Voice Concerns

Nevertheless, doctors and pharmacists have cautions that the sale of what remains an unlicensed medication in the United Kingdom is a cause for concern and could lead to individuals injecting products of uncertain source.

Some experts stated the demand for retatrutide could be connected to the increasing cost of licensed weight loss products such as Mounjaro.

Legal Status and Implementation

Selling the unapproved drug on social media or Telegram is prohibited in the UK, as it is an unapproved drug that cannot be marketed or distributed for personal consumption under the Human Medicines Regulations 2012.

Several content creators attempt to sidestep the rules by calling to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled substance, but advertising and distribution can still violate medicines, marketing, and consumer regulations, risking fines, prosecution or imprisonment.

Service Response and Content Removal

Based on TikTok, the service has taken down problematic content and prohibited associated keywords and search suggestions. The organization said it was dedicated to keeping the platform safe and investing in strengthening compliance measures.

Online Marketplace Activities

Investigations also found communities with up to 9,000 members marketing the experimental drug using the platform's integrated discovery tool, which operates like a public directory. Typing “retatrutide” instantly displays channels with thousands of members, populated with photos of slimming results, positive reviews and step-by-step instructions for mixing or administering at residence.

After minutes of entering one community, a vendor shared WhatsApp details, where most transactions occur. The vendor sent an instruction manual and guaranteed delivery within two days. When asked whether the product was authentic, one vendor said: “You can’t be sure.” Another provided a photo of a alleged laboratory certificate. None inquired about weight, medical conditions or previous experience.

Product Details and Pricing

Inside these communities, posts show black plastic parcels with Royal Mail stickers, stating to include fresh supplies. One message read: “It took eight of us to load them this morning.”

Buyers can select between dry substance containers, mixed at home with sterile water, or pre-filled injectors usually sold at 160 pounds for 20mg. When asked how much time a injector should last, sellers give conflicting answers ranging from a few weeks to “depends on your body”.

Service Oversight and Security Actions

A spokesperson for the messaging service stated it actively monitored dangerous material on its platform including content that promoted the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Warnings

“Individuals are administering substances they can’t verify. Although the science behind this drug is sound, these online versions may not contain what they claim,” said Jason Murphy, the director of pharmacy at a pharmacy service.

Dr Crystal Wyllie of an online medical service connected the increase in interest to recent cost increases for approved slimming drugs such as Mounjaro. “With prices increasing, patients are turning to online platforms. But fake treatments are extremely dangerous. You cannot know what’s contained or whether the conditions they were made in was sterile,” she explained.

Her team has previously encountered patients harmed by self-injection from unconfirmed sources. “We understand the frustration, but buying from messaging apps or WhatsApp is gambling with your well-being,” said the doctor. “These materials could be contaminated or incorrectly dosed.”

Manufacturer Position

A representative from Eli Lilly said retatrutide was in third stage research studies and had not been reviewed or approved by any regulatory agency anywhere in the world. “Therefore at this point no one can market [it] for personal consumption,” they explained, adding that any item “misleadingly claiming itself as a company investigational substance not yet approved … may expose patients to potentially serious health risks”.